Heather Johnson
Medical · Plymouth, MINPI 1366656449
Payments from drug & device makers
Across 86 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$374
- Lilly USA, LLC$193
- Pfizer$179
- Amgen$133
- Johnson & Johnson$129
- AstraZeneca$128
- plus $407 from 16 others
What the payments were for
- Food & beverage$1,544100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $374 |
| Lilly USA, LLC | 12 | $193 |
| Pfizer | 10 | $179 |
| Amgen | 7 | $133 |
| Johnson & Johnson | 6 | $129 |
| AstraZeneca | 8 | $128 |
| Exact Sciences | 3 | $63 |
| GSK | 3 | $53 |
| Amarin Pharma, Inc. | 2 | $36 |
| Boehringer Ingelheim | 2 | $32 |
| AbbVie | 2 | $27 |
| Biogen | 1 | $26 |
| Abbott | 1 | $22 |
| Radius Health, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Orexo US, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Seqirus USA Inc | 1 | $15 |
| Inspiremd Ltd | 1 | $14 |
| Novartis | 1 | $13 |
How this compares
$1,544 in reported general payments places this provider in the 70th percentile of 755 medical providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 27 | $42,568 |
| MounjaroTirzepatide | 18 | $18,600 |
| OzempicSemaglutide | 15 | $13,999 |
| XareltoRivaroxaban | 17 | $13,651 |
| Rosuvastatin Calcium | 132 | $2,302 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,644 |
| Atorvastatin Calcium | 163 | $1,640 |
| Telmisartan | 29 | $1,365 |
| PaxlovidNirmatrelvir/Ritonavir | 11 | $1,364 |
| Losartan Potassium | 119 | $1,326 |
| Levothyroxine Sodium | 126 | $1,307 |
| Escitalopram Oxalate | 65 | $980 |
| Ezetimibe | 18 | $908 |
| Labetalol Hcl | 12 | $648 |
| Pantoprazole Sodium | 26 | $630 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $179 | $43,93238 claims |
| Lilly USA, LLCMounjaro | $193 | $18,60018 claims |
| Novo NordiskOzempic | $374 | $13,99915 claims |
| Johnson & JohnsonXarelto | $129 | $13,65117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 755 medical providers in Michigan.
Other medical in Plymouth
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$66K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
- John BrabantDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.